Akari Therapeutics completes USD 5.5 million PIPE private placement financing

Akari Therapeutics Plc Sponsored ADR

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00
  • Akari completed a previously announced PIPE private placement, consolidating remaining closings into a single funding event on June 26, 2026.
  • Received about $8.3 million in total capital during Q2 2026, including about $2.8 million from warrant exercises in May.
  • Private placement covered 1,470,588 ADSs or prefunded warrants with Series H, Series I, Series J warrants for 1,470,588 ADSs.
  • Series H, Series I, Series J warrant issuance remains subject to shareholder approval at the June 30, 2026 annual meeting.
  • Proceeds earmarked to advance AKTX-101 toward a Phase 1 first-in-human trial, with IND-enabling work targeting mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290845PRIMZONEFULLFEED9753851) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.